Lifetime monoamine oxidase inhibition and sleep.
The effects of clorgyline, a type A monoamine oxidase (MAO) inhibitor, on the sleep of the rat were examined after subacute and lifetime administration. When 2 mg/kg 24 hours were given for 60 hours, type A MAO was inhibited by 92% and a significant reduction in REM sleep time was noted. When fetal rats were exposed to maternal dosage of 1 mg/kg/24 hours and then received this dose from one to 6 weeks postnatally, type A MAO was inhibited by 99%, but there were no alterations in the EEG sleep stages. In summary, subacute administration of clorgyline resulted in decreases in both Type A MAO and REM sleep; during chronic administration in a developing animal, Type A MAO was again decreased, but there was no corresponding change in REM sleep.
D000818:Animals; D001921:Brain / Q000254:growth & development / Q000378:metabolism; D003010:Clorgyline / Q000494:pharmacology; D004569:Electroencephalography; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012890:Sleep / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects
D008996:Monoamine Oxidase Inhibitors; D003010:Clorgyline